Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Citalopram. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 known ✓ | P31645 | 14/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 2/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 1/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.98 |
| ▸ | HTR2C | P28335 | 2/20 | 0.98 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.98 |
| ▸ | HRH1 | P35367 | 2/20 | 0.98 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.98 |
| ▸ | DRD3 | P35462 | 2/20 | 0.98 |
| ▸ | HTR2B | P41595 | 2/20 | 0.98 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.98 |
| ▸ | NPC1 | O15118 | 1/20 | 0.98 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.98 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.98 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.98 |
| ▸ | HTR1A | P08908 | 1/20 | 0.98 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.98 |
| ▸ | DRD1 | P21728 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Citalopram SCHEMBL1693551 | 1.00 | SLC6A4 (1.00) | SLC6A4MAPK1BLMPMP22NPSR1 | |
| Citalopram SCHEMBL1286979 | 1.00 | SLC6A4 (1.00) | SLC6A4MAPK1BLMPMP22NPSR1 | |
| Escitalopram SCHEMBL522164 | 1.00 | SLC6A4 (1.00) | SLC6A4MAPK1BLMPMP22NPSR1 | |
| Citalopram SCHEMBL41352 | 1.00 | SLC6A4 (1.00) | SLC6A4MAPK1BLMPMP22NPSR1 | |
| Citalopram SCHEMBL946 | 0.99 | SLC6A4 (1.00) | SLC6A4MAPK1BLMPMP22NPSR1 | |
| (R)-Citalopram SCHEMBL29414626 | 0.99 | SLC6A4 (1.00) | SLC6A4MAPK1BLMPMP22NPSR1 | |
| Citalopram SCHEMBL29494157 | 0.99 | SLC6A4 (1.00) | SLC6A4MAPK1BLMPMP22NPSR1 | |
| Escitalopram SCHEMBL34948 | 0.99 | SLC6A4 (1.00) | SLC6A4MAPK1BLMPMP22NPSR1 | |
| Citalopram SCHEMBL3858802 | 0.99 | SLC6A4 (1.00) | SLC6A4MAPK1BLMPMP22NPSR1 | |
| (R)-Citalopram SCHEMBL13235283 | 0.99 | SLC6A4 (1.00) | SLC6A4MAPK1BLMPMP22NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 6845 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122079853-A | N-substituted indoles and other heterocyclic compounds for the treatment of brain diseases | — | 2026-05-26 | — | — | CN | claimed |
| CN-110609095-B | Method for determining citalopram or a salt thereof and related substances in a formulation thereof | 苏州科伦药物研究有限公司 | 2026-05-15 | — | — | CN | claimed |
| EP-4279487-B1 | PURIFICATION METHOD FOR CITALOPRAM OR S-CITALOPRAM | ZHEJIANG HUAHAI PHARM CO LTD (CN) | 2026-04-29 | — | — | EP | claimed |
| EP-3931189-B1 | AZEPINO-INDOLES AND OTHER HETEROCYCLES FOR TREATING BRAIN DISORDERS | UNIV CALIFORNIA (US) | 2025-12-24 | — | — | EP | claimed |
| US-20250339483-A1 | EXTRACELLULAR VESICLES FROM MICROALGAE, THEIR BIODISTRIBUTION UPON INTRANASAL ADMINISTRATION, AND USES THEREOF | AGS THERAPEUTICS SAS (FR) | 2025-11-06 | — | — | US | claimed |
| EP-4608424-A1 | EXTRACELLULAR VESICLES FROM MICROALGAE, THEIR BIODISTRIBUTION UPON INTRANASAL ADMINISTRATION, AND USES THEREOF | AGS Therapeutics SAS (FR) | 2025-09-03 | — | — | EP | claimed |
| CN-116635375-B | Purification method of citalopram or S-citalopram | 浙江华海药业股份有限公司 | 2025-06-17 | — | — | CN | claimed |
| US-20250136548-A1 | FUNCTIONALIZED ALKYLAMINES | TERRAN BIOSCIENCES INC (US) | 2025-05-01 | — | — | US | claimed |
| CN-119896669-A | Comprises dextromethorphan pharmaceutical compositions of a compound containing a compound of formula (I) | 苏州恩华生物医药科技有限公司 | 2025-04-29 | — | — | CN | claimed |
| US-20250122164-A1 | N,N-DIMETHYLAMPHETAMINE ANALOGS FOR TREATING BRAIN DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2025-04-17 | — | — | US | claimed |
| WO-2002076461-A1 | COMBINATION OF REBOXETINE AND CITALOPRAM | DURSUN SERDAR MURAT (CA) | 2002-10-03 | — | — | WO | claimed |
| EP-1227088-A1 | Crystalline base of citalopram and hydrochoride or hydrobromide salt thereof | H.Lundbeck A/S (DK) | 2002-07-31 | — | — | EP | claimed |
| WO-2002053133-A1 | PHARMACEUTICAL COMPOSITION CONTAINING CITALOPRAM | H. LUNDBECK A/S (DK) | 2002-07-11 | — | — | WO | claimed |
| EP-1202721-A1 | CYCLOBENZAPRINE FOR TREATING GENERALIZED ANXIETY DISORDER AND COMPOSITIONS THEREOF | Vela Pharmaceuticals Inc. (US) | 2002-05-08 | — | — | EP | claimed |
| EP-1169314-A1 | CRYSTALLINE BASE OF CITALOPRAM | H. Lundbeck A/S (DK) | 2002-01-09 | — | — | EP | claimed |
| US-20010049450-A1 | Citalopram hydrobromide crystal and method for crystallization thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2001-12-06 | — | — | US | claimed |
| EP-1152000-A1 | Citalopram hydrobromide crystal and method for crystallization thereof | SUMIKA FINE CHEMICALS Co., Ltd. (JP) | 2001-11-07 | — | — | EP | claimed |
| WO-2001080619-A2 | PHARMACEUTICAL COMPOSITION CONTAINING CITALOPRAM | H. LUNDBECK A/S (DK) | 2001-11-01 | — | — | WO | claimed |
| WO-2001068627-A1 | CRYSTALLINE BASE OF CITALOPRAM | H. LUNDBECK A/S (DK) | 2001-09-20 | — | — | WO | claimed |
| WO-2001012174-A1 | CYCLOBENZAPRINE FOR TREATING GENERALIZED ANXIETY DISORDER AND COMPOSITIONS THEREOF | VELA PHARMACEUTICALS INC. (US) | 2001-02-22 | — | — | WO | claimed |